-
STAT News – Biotech2 weeks agoSTAT+: Pfizer’s Lyme vaccine results set up tricky regulatory path
Pfizer and Valneva’s Lyme disease vaccine cut cases by about 73% in a Phase 3 trial, but missed its primary statistical endpoint — setting up a...
-
STAT News – Biotech2 weeks agoMatch Day results show impact of federal immigration policy
Salutations from San Diego. This is Jonathan Wosen, West Coast biotech & life sciences reporter. We’ve got an outstanding lineup for you today, featuring a look...
-
Uncategorized2 weeks agoEMA launches tools to accelerate development of medicines
The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an...
-
Uncategorized2 weeks ago
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+
Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders.
-
Uncategorized2 weeks ago
FDA Warns of Seizure Risk With Some Parkinson’s Drugs
The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking carbidopa/levodopa drugs. Both AbbVie and Novartis market...
-
Uncategorized2 weeks ago
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design
Earendil Labs’ AI-centered platform has produced more than 40 programs, including anti-inflammatory assets that have attracted a pair of partnership agreements with Sanofi.
-
STAT News – Biotech2 weeks agoSTAT+: Doctronic raises $40 million as race to apply AI in clinical care heats up
Earlier this year the startup Doctronic launched a provocative, first-in-the-nation experiment to renew drug prescriptions with a chatbot. Now it’s refilling its coffers with $40 million...
-
Uncategorized2 weeks ago
Oryon Splashes Onto Parkinson’s Scene With $42M for Cell Therapy
Oryon Cell Therapies’ lead cell therapy is an autologous treatment designed to replace dopaminergic neurons in patients with Parkinson’s disease. Phase 1b/2a data showed that the...
-
Endpoints News2 weeks ago
Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss
Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results. Monday’s Phase 2 maintenance...
-
Endpoints News2 weeks ago
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection
Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting — possibly...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Terns rebuffed a higher bid before selling to Merck
